Marksans Pharma Limited (MARKSANS.NS)
INR 211.44
(-0.97%)
INR 211.44
(-0.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 7.79 Billion INR | 33.56% |
| 2022 | 2.87 Billion INR | 34.39% |
| 2021 | 2.14 Billion INR | -30.76% |
| 2020 | 3.09 Billion INR | 81.64% |
| 2019 | 1.7 Billion INR | 55.7% |
| 2018 | 1.09 Billion INR | 111.89% |
| 2017 | 515.98 Million INR | 232.27% |
| 2016 | 155.29 Million INR | -85.47% |
| 2015 | 1.06 Billion INR | -31.46% |
| 2014 | 1.55 Billion INR | 80.4% |
| 2013 | 864.11 Million INR | 98.43% |
| 2012 | 435.47 Million INR | 135.86% |
| 2011 | -1.21 Billion INR | -3631.73% |
| 2010 | -32.53 Million INR | -130.88% |
| 2009 | 105.37 Million INR | -50.62% |
| 2008 | 213.38 Million INR | -25.43% |
| 2007 | 286.14 Million INR | 58.5% |
| 2006 | 180.52 Million INR | -42.52% |
| 2005 | 314.06 Million INR | 25.28% |
| 2004 | 250.67 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.07 Billion INR | 21.91% |
| 2023 Q2 | 1.15 Billion INR | 30.68% |
| 2023 Q3 | 1.15 Billion INR | 0.37% |
| 2023 Q1 | 883.06 Million INR | -17.17% |
| 2023 FY | 3.84 Billion INR | 33.56% |
| 2023 Q4 | 885.87 Million INR | -23.51% |
| 2022 Q4 | 1.06 Billion INR | 30.73% |
| 2022 Q2 | 803.68 Million INR | 30.16% |
| 2022 FY | 2.87 Billion INR | 34.39% |
| 2022 Q1 | 617.46 Million INR | 46.03% |
| 2022 Q3 | 815.54 Million INR | 1.48% |
| 2021 Q3 | 492.44 Million INR | -6.58% |
| 2021 Q1 | 698.66 Million INR | -36.08% |
| 2021 FY | 2.14 Billion INR | -30.76% |
| 2021 Q2 | 527.11 Million INR | -24.55% |
| 2021 Q4 | 422.82 Million INR | -14.14% |
| 2020 Q3 | 824.6 Million INR | 28.51% |
| 2020 Q2 | 641.64 Million INR | 2.22% |
| 2020 Q1 | 627.7 Million INR | 5.18% |
| 2020 FY | 3.09 Billion INR | 81.64% |
| 2020 Q4 | 1.09 Billion INR | 32.55% |
| 2019 Q3 | 399.58 Million INR | 39.76% |
| 2019 Q1 | 276.87 Million INR | 88.8% |
| 2019 Q4 | 596.77 Million INR | 49.35% |
| 2019 Q2 | 285.91 Million INR | 3.27% |
| 2019 FY | 1.7 Billion INR | 55.7% |
| 2018 Q4 | 146.64 Million INR | -52.92% |
| 2018 Q3 | 311.5 Million INR | -1.37% |
| 2018 Q2 | 315.84 Million INR | 6.98% |
| 2018 FY | 1.09 Billion INR | 111.89% |
| 2018 Q1 | 295.22 Million INR | 377.96% |
| 2017 FY | 515.98 Million INR | 232.27% |
| 2017 Q4 | -106.21 Million INR | -149.99% |
| 2017 Q3 | 212.46 Million INR | 45.78% |
| 2017 Q2 | 145.74 Million INR | -25.86% |
| 2017 Q1 | 196.57 Million INR | 1547.85% |
| 2016 Q3 | 152.07 Million INR | 3203.47% |
| 2016 Q2 | -4.9 Million INR | -122.57% |
| 2016 Q1 | 21.71 Million INR | 400.6% |
| 2016 Q4 | -13.57 Million INR | -108.93% |
| 2016 FY | 155.29 Million INR | -85.47% |
| 2015 Q2 | 430.34 Million INR | -4.16% |
| 2015 FY | 1.06 Billion INR | -31.46% |
| 2015 Q3 | 184.84 Million INR | -57.05% |
| 2015 Q4 | 4.33 Million INR | -97.65% |
| 2015 Q1 | 449.02 Million INR | 23.67% |
| 2014 Q1 | 352.21 Million INR | 107.58% |
| 2014 Q4 | 363.07 Million INR | -13.86% |
| 2014 Q3 | 421.49 Million INR | -0.14% |
| 2014 FY | 1.55 Billion INR | 80.4% |
| 2014 Q2 | 422.08 Million INR | 19.84% |
| 2013 Q4 | 169.67 Million INR | -37.08% |
| 2013 Q3 | 269.65 Million INR | 19.92% |
| 2013 Q1 | 199.91 Million INR | -46.13% |
| 2013 FY | 864.11 Million INR | 98.43% |
| 2013 Q2 | 224.86 Million INR | 12.48% |
| 2012 Q1 | -127.84 Million INR | 0.0% |
| 2012 FY | 435.47 Million INR | 135.86% |
| 2012 Q4 | 371.08 Million INR | 201.66% |
| 2012 Q3 | 123.01 Million INR | -31.7% |
| 2012 Q2 | 180.1 Million INR | 240.87% |
| 2011 FY | -1.21 Billion INR | -3631.73% |
| 2010 FY | -32.53 Million INR | -130.88% |
| 2009 FY | 105.37 Million INR | -50.62% |
| 2008 FY | 213.38 Million INR | -25.43% |
| 2007 FY | 286.14 Million INR | 58.5% |
| 2006 FY | 180.52 Million INR | -42.52% |
| 2005 FY | 314.06 Million INR | 25.28% |
| 2004 FY | 250.67 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 43.515% |
| Cipla Limited | 105.7 Billion INR | 92.629% |
| Gland Pharma Limited | 16.45 Billion INR | 52.64% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 42.717% |
| Kopran Limited | 675.44 Million INR | -1053.546% |
| NGL Fine-Chem Limited | 416.27 Million INR | -1771.759% |
| Pfizer Limited | 9.61 Billion INR | 18.936% |
| Sanofi India Limited | 12.19 Billion INR | 36.098% |
| SMS Pharmaceuticals Limited | 1.34 Billion INR | -481.399% |
| TTK Healthcare Limited | 249.89 Million INR | -3018.008% |